TOI

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oncology Institute Inc revenue for the last quarter amounts to 136.56M USD, increased 36.70 % YoY.

Oncology Institute Inc. EPS for the last quarter amounts to -0.14 USD, decreased -22.22 % YoY.

Oncology Institute Inc (TOI) has 825 emplpoyees as of December 16 2025.

Today TOI has the market capitalization of 370.90M USD.